Irbesartan Tablet
Product Images NDC 70518-1543

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Irbesartan (NDC 70518-1543). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Irbesartan 300mg 70518 1543 01

Irbesartan 300mg 70518 1543 01
Irbesartan Tablet 300 mg oral tablets in a quantity of 90, repackaged by RemedyRepack Inc. The label includes storage instructions and manufacturer information, showing the tablet as oval and white. The product is marked for prescription use only.*
FDA Label Image

Structure (Spl Image1 Structure)

Structure (Spl Image1 Structure)
Chemical structure diagram of Irbesartan, depicting its molecular framework including rings and functional groups as shown in the image.*
FDA Label Image

Figure 1 (Spl Image2 Figure1)

Figure 1 (Spl Image2 Figure1)
A scatter plot with a trend line showing the relationship between Irbesartan dose in mg/day (x-axis) and placebo-subtracted reduction in trough SeSBP in mmHg (y-axis), illustrating an integrated analysis of this dose-response effect.*
FDA Label Image

Figure 2 (Spl Image3 Figure2)

Figure 2 (Spl Image3 Figure2)
A line graph titled 'Figure 2' showing the placebo-subtracted reduction in trough SeDBP (mmHg) as a function of Irbesartan dose (mg/day), with data points scattered and a curve fitting the integrated analysis.*
FDA Label Image

Figure 3 (Spl Image4 Figure3)

Figure 3 (Spl Image4 Figure3)
A line graph showing cumulative event rates over months of follow-up for three groups: Irbesartan, Amlodipine, and Placebo. The x-axis represents months of follow-up from 0 to 60, and the y-axis shows cumulative event rate percentages up to 75%. A small inset compares relative risk (RR) and p-values for Irbesartan versus Placebo and Irbesartan versus Amlodipine.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.